[Pharmaco-economic aspects of antibiotic therapy in hospitals].
Amongst medications used in hospitals, antibiotics represent the most expensive therapeutic group; their use is constantly growing. Beyond acquisition costs, antibiotherapy costs must be approached at a broader level, including costs of preparation, administration, efficacy or inefficacy, monitoring, side effects treatment, and long-term costs resulting bacteria resistance. An attempt to cost containment in antibiotherapy can only result from a global, multidisciplinary strategy, with at all levels, as main objectives, the improvement of the quality and effectiveness of treatment adequate relevance of drug selection and therapy assessment.
Delporte
J P
JP
Service de Pharmacie, Université de Liège.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D002985:Clinical Protocols; D003363:Cost Control; D003365:Costs and Cost Analysis; D016527:Drug Costs; D016903:Drug Monitoring / Q000191:economics; D004352:Drug Resistance, Microbial; D004363:Drug Utilization; D004469:Economics, Hospital; D017850:Economics, Pharmaceutical; D006801:Humans; D011787:Quality of Health Care; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents